The CGM market is an exciting, fast-growing, multibillion-dollar sector for the medical device industry, according to our latest Medtech Market Intelligence Report for MassDevice.
The report on the CGM market — available for purchase on MassDevice — draws on numerous sources, including but not limited to: medical associations, government data, medical journals, leading medtech publications, clinical data, prevalence/statistical data, financial reports/10Ks, quarterlies, investor presentations/webcasts, company press releases, and product information derived directly from manufacturers.
It’s little wonder that the CGM market is so fast-growing. It’s probably safe to say that nearly everyone should monitor their glucose occasionally, but for people with diabetes, using CGMs can be life-changing. They’re helping to manage an extremely burdensome and complicated disease that affects hundreds of millions of people worldwide and is only expected to grow.
Purchase the report to gain a deep understanding of the CGM market, including an overall global market forecast (2025-2030), forecasts for the U.S. and OUS, and sales projections for major CGM companies including Abbott, Dexcom, Medtronic (soon to be MiniMed), and Senseonics.
Here are 12 high-level insights from the report:
1. A huge population of people could benefit from CGMs
The global diabetes population of approximately 600 million is nearly twice the U.S. population and is fast-growing. Think of nearly two United States full of people with diabetes. (The U.S. population stands at roughly 340-plus million). It’s astounding.
2. A market worth tens of billions of dollars
The CGM market is one of the largest medical device markets in the world, in the tens of billions of dollars. (It’s the largest sector I’ve ever forecast, that’s for sure). Disposable sensors are repeat sales, and very lucrative.
3. The CGM market is fast-growing, too
The momentum of revenue growth isn’t slowing anytime soon, advancing in the double-digits (mid- to high-teens) over the next five years, with total sales nearly doubling by 2030.
4. Abbott is particularly a standout
The market leader, Abbott, has been recording record sales increases of approximately $1 billion a year for the past 2–3 years. The FreeStyle Libre CGM portfolio is the company’s “most successful medical device of all time.”
5. Dexcom continues to pioneer new CGM innovations
The wearable CGM pioneer Dexcom is the first to produce many innovations, including the first well-connected CGM, the first with an Urgent Low feature, the first to incorporate GenAI — and the company’s CGM revenues are also growing at a double-digit rate. Note: People with diabetes have different CGM model & app preferences, so each competitor is a little different, giving patients options. Many probably switch between models and manufacturers.
6. There is room for everyone to grow in the CGM market
The CGM market is vastly underpenetrated, leaving room for substantial growth for all competitors (e.g., Abbott and Dexcom report a combined estimated user base of only 10 million, but the population of diabetes is nearly 600 million and growing).
7. Expanding beyond type 1 diabetes
CGM manufacturers are expanding indications from the traditional type 1 market to all types of diabetes (e.g., insulin and non-insulin using type 2, gestational diabetes, prediabetes, and even health-conscious consumers, who should also check blood sugar at least every now and then to prevent prediabetes).
8. CGM sensors are getting increasingly smaller and more discreet
Abbott’s newest FreeStyle Libre 2/3 Plus CGMs (and new custom Instinct sensor for Medtronic’s MiniMed 780G) are now the smallest and thinnest in the world. Sensor miniaturization and comfort are key.
9. The pairing of CGMs and insulin pumps
CGMs go hand-in-hand with popular and growing automated insulin pump systems for people with type 1 diabetes, another closely-related, growing medtech market.
10. Senseonics’ implantable CGM that lasts for an entire year
Senseonics is pioneering the first 365-day implantable CGM. And several new startups with innovative “wearables” have emerged to compete in this market.
11. It’s not just about eliminating fingersticks; it’s about improving overall health
It’s an important clinical point boosting sales: CGMs not only eliminate painful fingersticks (from traditional blood glucose meters), but have been proven to help people with diabetes substantially improve glucose “time in range (TIR)” — or to maintain glucose within 70-180mg/dl at least 70% of time — and lower A1C to reduce numerous potentially dangerous complications resulting from high or low blood glucose. CGMs are now well-accepted “therapies” (not just monitoring devices) as they’re helping to improve diabetes outcomes!
12. The CGM market has a role in reducing overall healthcare costs
Diabetes healthcare costs have been spiraling out of control and now total nearly $415 billion in the U.S. alone – and CGMs are helping to reduce these costs by substantially reducing complications.
Click here to purchase MassDevice’s Medtech Market Intelligence Report about the CGM market.
Chrystal Larsen is an established medtech writer/editor and market analyst with experience working for major medical data publishers, such as Elsevier and Informa, and freelancing/consulting for the medical device and pharmaceutical industries. Her portfolio includes producing informative nedtech intelligence reports covering high-growth segments, including diabetes technologies, neuromodulation, and other key diagnostic and therapeutic areas. Her skills encompass a long history of medical/scientific content development, insightful strategic market and analysis, and marketing/communications, producing educational and promotional deliverables that provide timely and valuable intelligence for corporations, investors, and healthcare professionals.
